3m Innovative Properties Company

Zoetis Services LLC

Solventum Intellectual Properties Company

Minghua Dai

Jie Jerry Liu

Robert T Fitzsimons, Jr

Amy K McNulty

Jana Ninkovic

Federica Sgolastra

Stephen B Roscoe

Myungchan Kang

Evan D Brutinel

Steven Alan Dunham

Jesse D Miller

Hsi-Chou Liu

Renee K Cline

Lisa Marie Bergeron

Graeme Bainbridge

Lei Zhang

Kurt J Halverson

Ta-Hua Yu

Junkang Jacob Liu

David R Holm

Graham M Clarke

Paul D Wightman

Joseph C Spagnola

Kiu-Yuen Tse

Wei Zhang

Bryan A Baker

Dmitri V Smirnov

Stephen A O Olson

Amy K Mcnulty

Robert T Fitzsimons

Jie Liu

An article. The article includes a substrate, wherein the substrate having two opposing major surfaces; and particles coated with a metal oxide on the substrate: particles coated with a metal on the substrate; wherein the coated particles are randomly distributed on or in the substrate; and wherein at least some of coated particles are discrete particles.

Anti-microbial articles

An article, including a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site and a second surface opposite the first surface; wherein at least one of the interconnected polymeric stand has a plurality of features extending from the first surface of the interconnected polymeric strands; wherein at least one of the interconnected polymeric strands is non-linear; a plurality of openings between adjacent interconnected polymeric strands; an adhesive layer in contact with the second surface of the interconnected polymeric strands; and a filler in contact with the adhesive layer, the adhesive layer in between the network of interconnected polymeric strands and the filler; wherein the article is a negative pressure wound therapy article.

Negative pressure wound therapy article with features

A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.

Peptides for binding epidermal growth factor

A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.

Assay devices are provided including a receptacle having a sample entry port; a plunger disposed within the receptacle; at least one reagent; a membrane attached to a first surface of the plunger; a wick providing capillary force; and a detection zone. The membrane includes a target conjugate zone in which affinity components are disposed. Capture compounds are immobilized in a detection zone, which is located between the target conjugate zone and the wick. A method of detecting a target analyte is also provided, including providing the assay device; providing a sample suspected to contain a target analyte; adding the sample onto the device; allowing the sample to travel along the membrane until the sample reaches the detection zone; immobilizing the target analyte through reaction of the target analyte with the capture compounds; reacting the immobilized target analyte with a reagent to generate a detectable signal; and detecting the generated signal.

Assay devices and method of detecting a target analyte

The present disclosure describes novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further describes use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Caninized anti-NGF antibodies and methods thereof

Skin penetration enhancers comprising peptides are disclosed. Compositions comprising the skin penetration enhancers are also provided. The compositions further comprise an active agent, such as a pharmaceutically active agent, a vaccine, a cosmetic agent, and a. nutritional supplement. Methods of transdermal ly delivering a pharmaceutically active agent, a vaccine, a cosmetic agent, or a nutritional supplement are also provided.

Peptides for enhancing transdermal delivery

The present disclosure encompasses novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Growing community of inventors

Plymouth, MN, United States of America

Minghua Dai